Development and validation of a hypoxia- and mitochondrial dysfunction- related prognostic model based on integrated single-cell and bulk RNA sequencing analyses in gastric cancer

• Published in: Frontiers in immunology Vol. 15; p. 1419133
• Main Authors: Li, Yirong, Cui, Yue, Wang, Zhen, Wang, Liwei, Yu, Yi, Xiong, Yuyan
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 06.08.2024
• Subjects: Biomarkers, Tumor - genetics; Cell Line, Tumor; Female; gastric cancer; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; hypoxia; Immunology; immunotherapy; Male; Middle Aged; Mitochondria - genetics; Mitochondria - metabolism; mitochondrial dysfunction; Plasminogen Activator Inhibitor 1 - genetics; Prognosis; Sequence Analysis, RNA; Single-Cell Analysis; Stomach Neoplasms - genetics; Stomach Neoplasms - immunology; Stomach Neoplasms - mortality; Transcriptome; Tumor Microenvironment - genetics; Tumor Microenvironment - immunology; hypoxia; mitochondrial dysfunction; model; gastric cancer; prognosis; immunotherapy
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2024.1419133

Gastric cancer (GC) remains a major global health threat ranking as the fifth most prevalent cancer. Hypoxia, a characteristic feature of solid tumors, significantly contributes to the malignant progression of GC. Mitochondria are the major target of hypoxic injury that promotes mitochondrial dysfunction during the development of cancers including GC. However, the gene signature and prognostic model based on hypoxia- and mitochondrial dysfunction-related genes (HMDRGs) in the prediction of GC prognosis have not yet been established. The gene expression profile datasets of stomach cancer patients were retrieved from The Cancer Genome Atlas and the Gene Expression Omnibus databases. Prognostic genes were selected using Least Absolute Shrinkage and Selection Operator Cox (LASSO-Cox) regression analysis to construct a prognostic model. Immune infiltration was evaluated through ESTIMATE, CIBERSORT, and ssGSEA analyses. Tumor immune dysfunction and exclusion (TIDE) and immunophenoscore (IPS) were utilized to explore implications for immunotherapy. Furthermore, in vitro experiments were conducted to validate the functional roles of HMDRGs in GC cell malignancy. In this study, five HMDRGs (ZFP36, SERPINE1, DUSP1, CAV1, and AKAP12) were identified for developing a prognostic model in GC. This model stratifies GC patients into high- and low-risk groups based on median risk scores. A nomogram predicting overall survival (OS) was constructed and showed consistent results with observed OS. Immune infiltration analysis indicated that individuals in the high-risk group tend to exhibit increased immune cell infiltration. Additionally, analysis of cancer immunotherapy responses revealed that high-risk group patients exhibit poorer responses to cancer immunotherapy compared to the low-risk group. Immunohistochemistry (IHC) staining indicated that the expression levels of HMDRGs were remarkably correlated with GC, of which, SERPINE1 displayed the most pronounced up-regulation, while ZFP36 exhibited the most notable down-regulation in GC patients. Furthermore, investigation validated that SERPINE1 and ZFP36 contribute to the malignant processes of GC cells correlated with mitochondrial dysfunction. This study presents a novel and efficient approach to evaluate GC prognosis and immunotherapy efficacy, and also provides insights into understanding the pathogenesis of GC.